Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc. Common Stock (MSLE) Stock Competitors & Peer Comparison
See (MSLE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MSLE | $11.35 | +2.16% | 14.5M | 4.37 | $2.57 | N/A |
| ONC | $365.81 | +3.20% | 38.7B | 724.28 | $0.50 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | N/A |
| DFTX | $16.80 | -2.75% | 1.7B | N/A | N/A | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LFMDP | $22.68 | -0.09% | 998.4M | -10.06 | -$2.26 | N/A |
| CGEM | $14.12 | +1.73% | 806.4M | -4.11 | -$3.32 | N/A |
| ATAI | $3.86 | +0.95% | 731.9M | -4.67 | -$0.83 | N/A |
| HITI | $2.50 | +3.96% | 218.7M | -5.41 | -$0.46 | N/A |
Stock Comparison
MSLE vs ONC Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, ONC has a market cap of 38.7B. Regarding current trading prices, MSLE is priced at $11.35, while ONC trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas ONC's P/E ratio is 724.28. In terms of profitability, MSLE's ROE is N/A, compared to ONC's ROE of +0.02%. Regarding short-term risk, MSLE is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check ONC's competition here
MSLE vs WBA Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, MSLE is priced at $11.35, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas WBA's P/E ratio is -1.64. In terms of profitability, MSLE's ROE is N/A, compared to WBA's ROE of -0.70%. Regarding short-term risk, MSLE is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check WBA's competition here
MSLE vs DFTX Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, DFTX has a market cap of 1.7B. Regarding current trading prices, MSLE is priced at $11.35, while DFTX trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas DFTX's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to DFTX's ROE of -0.86%. Regarding short-term risk, MSLE is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check DFTX's competition here
MSLE vs HROWL Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, MSLE is priced at $11.35, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas HROWL's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to HROWL's ROE of -0.09%. Regarding short-term risk, MSLE is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HROWL's competition here
MSLE vs HROWM Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, MSLE is priced at $11.35, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas HROWM's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to HROWM's ROE of -0.09%. Regarding short-term risk, MSLE is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HROWM's competition here
MSLE vs LFMDP Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, LFMDP has a market cap of 998.4M. Regarding current trading prices, MSLE is priced at $11.35, while LFMDP trades at $22.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas LFMDP's P/E ratio is -10.06. In terms of profitability, MSLE's ROE is N/A, compared to LFMDP's ROE of +2.22%. Regarding short-term risk, MSLE is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check LFMDP's competition here
MSLE vs CGEM Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, CGEM has a market cap of 806.4M. Regarding current trading prices, MSLE is priced at $11.35, while CGEM trades at $14.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas CGEM's P/E ratio is -4.11. In terms of profitability, MSLE's ROE is N/A, compared to CGEM's ROE of -0.42%. Regarding short-term risk, MSLE is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check CGEM's competition here
MSLE vs ATAI Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, ATAI has a market cap of 731.9M. Regarding current trading prices, MSLE is priced at $11.35, while ATAI trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas ATAI's P/E ratio is -4.67. In terms of profitability, MSLE's ROE is N/A, compared to ATAI's ROE of -1.08%. Regarding short-term risk, MSLE is less volatile compared to ATAI. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check ATAI's competition here
MSLE vs HITI Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, HITI has a market cap of 218.7M. Regarding current trading prices, MSLE is priced at $11.35, while HITI trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas HITI's P/E ratio is -5.41. In terms of profitability, MSLE's ROE is N/A, compared to HITI's ROE of -0.40%. Regarding short-term risk, MSLE is less volatile compared to HITI. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check HITI's competition here
MSLE vs LFMD Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, LFMD has a market cap of 135.7M. Regarding current trading prices, MSLE is priced at $11.35, while LFMD trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas LFMD's P/E ratio is -11.28. In terms of profitability, MSLE's ROE is N/A, compared to LFMD's ROE of +2.22%. Regarding short-term risk, MSLE is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check LFMD's competition here
MSLE vs LFLY Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, MSLE is priced at $11.35, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas LFLY's P/E ratio is -0.04. In terms of profitability, MSLE's ROE is N/A, compared to LFLY's ROE of +0.25%. Regarding short-term risk, MSLE is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check LFLY's competition here
MSLE vs YI Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, YI has a market cap of 70.9M. Regarding current trading prices, MSLE is priced at $11.35, while YI trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas YI's P/E ratio is -2.82. In terms of profitability, MSLE's ROE is N/A, compared to YI's ROE of +0.11%. Regarding short-term risk, MSLE is less volatile compared to YI. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check YI's competition here
MSLE vs PETS Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, PETS has a market cap of 63.1M. Regarding current trading prices, MSLE is priced at $11.35, while PETS trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas PETS's P/E ratio is -0.95. In terms of profitability, MSLE's ROE is N/A, compared to PETS's ROE of -1.22%. Regarding short-term risk, MSLE is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check PETS's competition here
MSLE vs RAD Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, MSLE is priced at $11.35, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas RAD's P/E ratio is -0.05. In terms of profitability, MSLE's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, MSLE is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check RAD's competition here
MSLE vs KYNB Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, KYNB has a market cap of 33.7M. Regarding current trading prices, MSLE is priced at $11.35, while KYNB trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas KYNB's P/E ratio is -0.65. In terms of profitability, MSLE's ROE is N/A, compared to KYNB's ROE of -1.26%. Regarding short-term risk, MSLE is less volatile compared to KYNB. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check KYNB's competition here
MSLE vs RNTX Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, RNTX has a market cap of 31.8M. Regarding current trading prices, MSLE is priced at $11.35, while RNTX trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas RNTX's P/E ratio is -0.41. In terms of profitability, MSLE's ROE is N/A, compared to RNTX's ROE of -2.17%. Regarding short-term risk, MSLE is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check RNTX's competition here
MSLE vs POM Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, POM has a market cap of 23.7M. Regarding current trading prices, MSLE is priced at $11.35, while POM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas POM's P/E ratio is -4.43. In terms of profitability, MSLE's ROE is N/A, compared to POM's ROE of +0.07%. Regarding short-term risk, MSLE is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check POM's competition here
MSLE vs MEDS Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, MSLE is priced at $11.35, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas MEDS's P/E ratio is -0.31. In terms of profitability, MSLE's ROE is N/A, compared to MEDS's ROE of -0.26%. Regarding short-term risk, MSLE is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check MEDS's competition here
MSLE vs CJJD Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, MSLE is priced at $11.35, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas CJJD's P/E ratio is -0.46. In terms of profitability, MSLE's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, MSLE is less volatile compared to CJJD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check CJJD's competition here
MSLE vs NEUP Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, NEUP has a market cap of 8.2M. Regarding current trading prices, MSLE is priced at $11.35, while NEUP trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas NEUP's P/E ratio is -1.08. In terms of profitability, MSLE's ROE is N/A, compared to NEUP's ROE of -0.08%. Regarding short-term risk, MSLE is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check NEUP's competition here
MSLE vs SSY Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, MSLE is priced at $11.35, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas SSY's P/E ratio is -2.86. In terms of profitability, MSLE's ROE is N/A, compared to SSY's ROE of -0.18%. Regarding short-term risk, MSLE is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check SSY's competition here
MSLE vs HKPD Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, HKPD has a market cap of 7.5M. Regarding current trading prices, MSLE is priced at $11.35, while HKPD trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas HKPD's P/E ratio is 4.00. In terms of profitability, MSLE's ROE is N/A, compared to HKPD's ROE of -0.01%. Regarding short-term risk, MSLE is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check HKPD's competition here
MSLE vs AIXC Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, AIXC has a market cap of 6.4M. Regarding current trading prices, MSLE is priced at $11.35, while AIXC trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas AIXC's P/E ratio is 0.44. In terms of profitability, MSLE's ROE is N/A, compared to AIXC's ROE of -0.73%. Regarding short-term risk, MSLE is less volatile compared to AIXC. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check AIXC's competition here
MSLE vs BGMSP Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, BGMSP has a market cap of 6M. Regarding current trading prices, MSLE is priced at $11.35, while BGMSP trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas BGMSP's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, MSLE is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check BGMSP's competition here
MSLE vs MDVL Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, MSLE is priced at $11.35, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas MDVL's P/E ratio is -0.05. In terms of profitability, MSLE's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, MSLE is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check MDVL's competition here
MSLE vs ATNFW Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, MSLE is priced at $11.35, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas ATNFW's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, MSLE is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check ATNFW's competition here
MSLE vs NVOH Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, NVOH has a market cap of 2.3M. Regarding current trading prices, MSLE is priced at $11.35, while NVOH trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas NVOH's P/E ratio is 13.37. In terms of profitability, MSLE's ROE is N/A, compared to NVOH's ROE of +0.00%. Regarding short-term risk, MSLE is less volatile compared to NVOH. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check NVOH's competition here
MSLE vs BGMS Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, MSLE is priced at $11.35, while BGMS trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas BGMS's P/E ratio is -0.07. In terms of profitability, MSLE's ROE is N/A, compared to BGMS's ROE of -1.87%. Regarding short-term risk, MSLE is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check BGMS's competition here
MSLE vs AZNH Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, MSLE is priced at $11.35, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas AZNH's P/E ratio is 38.35. In terms of profitability, MSLE's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, MSLE is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check AZNH's competition here
MSLE vs LFLYW Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, MSLE is priced at $11.35, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, MSLE's ROE is N/A, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, MSLE is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check LFLYW's competition here
MSLE vs BIMI Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, MSLE is priced at $11.35, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas BIMI's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to BIMI's ROE of -2.94%. Regarding short-term risk, MSLE is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check BIMI's competition here
MSLE vs POZN Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, MSLE is priced at $11.35, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas POZN's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, MSLE is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check POZN's competition here
MSLE vs IPXL Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, MSLE is priced at $11.35, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas IPXL's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, MSLE is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check IPXL's competition here
MSLE vs ESRX Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, MSLE is priced at $11.35, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas ESRX's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, MSLE is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check ESRX's competition here
MSLE vs CPD Comparison February 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 14.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, MSLE is priced at $11.35, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 4.37, whereas CPD's P/E ratio is N/A. In terms of profitability, MSLE's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, MSLE is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check CPD's competition here